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BACKGROUND: African Americans have higher cancer
mortality rates than whites. Understanding the relative
contribution of cancer incidence, stage at diagnosis and
survival after diagnosis to the racial gap in life expectancy
has important implications for directing future health
disparity interventions toward cancer prevention, screen-
ing and treatment.
OBJECTIVE: We estimated the degree to which higher
cancer mortality among African Americans is due to
higher incidence rates, later stage at diagnosis or worse
survival after diagnosis.
DESIGN: Stochastic model of cancer incidence and
survival after diagnosis.
PATIENTS: Surveillance and Epidemiology End Result
cancer registry and National Health Interview Survey
data.
MEASUREMENTS: Life expectancy if African Americans
had the same cancer incidence, stage and survival after
diagnosis as white adults.
RESULTS: African-American men and women live 1.47
and 0.91 fewer years, respectively, than whites as the
result of all cancers combined. Among men, racial
differences in cancer incidence, stage at diagnosis and
survival after diagnosis account for 1.12 (95% CI: 0.52
to 1.36), 0.17 (95% CI: −0.03 to 0.33) and 0.21 (95% CI:
0.05 to 0.34) years of the racial gap in life expectancy,
respectively. Among women, incidence, stage and sur-
vival after diagnosis account for 0.41 (95% CI: −0.29 to
0.60), 0.26 (95% CI: −0.06 to 0.40) and 0.31 (95% CI:
0.05 to 0.40) years, respectively. Differences in stage
had a smaller impact on the life expectancy gap
compared with the impact of incidence. Differences in
cancer survival after diagnosis had a significant impact
for only two cancers—breast (0.14 years; 95% CI:
0.05 to 0.16) and prostate (0.05 years; 95% CI 0.01 to
0.09).
CONCLUSIONS: In addition to breast and colorectal
cancer screening, national efforts to reduce disparities
in life expectancy should also target cancer prevention,
perhaps through smoking cessation, and differences in
survival after diagnosis among persons with breast and
prostate cancer.
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INTRODUCTION
African Americans have higher mortality rates than whites
from a variety of cancers, including colon, breast, uterine,
cervical, lung and prostate cancer.1–7 These differences occur
because African Americans have higher incidence rates,
present at a later stage and have worse survival after
diagnosis.8–10 Previous studies have not examined how cancer
incidence, stage and survival after diagnosis influence mortality
on a common metric, such as life expectancy, nor have they
quantified the degree towhich racial differences in life expectancy
are due to racial differences in cancer incidence, stage or survival
after diagnosis.
Greater emphasis is now being placed on finding ways to
reduce disparities in health outcomes rather than merely
documenting their existence.11 The recent National Healthcare
Disparities Report has focused on disparities in incidence,
screening and mortality rates for breast and colorectal cancer
and has specifically targeted mammography and colonoscopy
use.12,13 As we move toward developing and implementing
interventions, however, understanding the absolute and rela-
tive impact that disparities in cancer incidence, stage at
presentation and survival after diagnosis have on the racial
gap in life expectancy could help to identify other key targets
for interventions, including whether we should also focus on
other cancers, on primary prevention or on disparities in
cancer treatment. Therefore, in this study, we analyzed data
from the Surveillance and Epidemiology End Result (SEER)
cancer registry and the National Health Interview Survey
(NHIS) to estimate the contribution of racial differences in
cancer incidence, stage at diagnosis and survival after diagnosis
to the racial difference in life expectancy.
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We used the Racial Disparities Simulation Model to simulate
cause-specific mortality events for a cohort of non-Hispanic
African American and white adults (described elsewhere in
greater detail14,15). This model uses mortality risks estimated
from NHIS and linked vital statistics death data. We extended
this model by simulating cancer incidence and fatality, the
risks of which were estimated from SEER data. This study was
granted exemption from IRB review.
Data
NHIS is an annual cross-sectional study of non-institutionalized
persons in the US. Data collected between 1986 and 1994 are
linked to vital statistics data through 2001.16,17 We analyzed
the 2003 public-use release version of SEER, which is a
population-based cancer registry of clinical, treatment and
outcome data, from 12 geographic regions around the US—
the 9 SEER sites [San Francisco/Oakland, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget Sound),
Utah and Atlanta] plus Alaska, San Jose-Monterey and Los
Angeles.18,19 We analyzed information on race, sex, age at
diagnosis, type of cancer, stage of diagnosis and cause of death
among 2,711,710 white and 291,126 African-American patients
with a primary or subsequent cancer, not including metastatic
sites of cancer, occurring between 1992 and 2000.
Risk Estimates
Using SEER data and concurrent census estimates of popula-
tion at risk provided by SEER,19 we estimated age (1-year
intervals), race (non-Hispanic African American vs. non-
Hispanic white) and sex-specific cancer incidence risk by
cancer type and stage by calculating incidence density rates.20
We used locally linear regression (Loess procedure in SAS) to
smooth these risk estimates across 1-year age intervals.21
We used parametric survival methods to estimate the
annual cancer mortality risk from time of diagnosis. For each
cancer and stage, we chose a specific parametric distribution
based on comparison of parametric and non-parametric
hazard plots. In instances when the survival data did not fit
any standard distributions, we used piecewise exponential
methods.22 We estimated cancer fatality risk for each cancer
type and stage as a function of age at diagnosis (10-year
intervals), race, sex and all two-way interactions between race
and other covariates.
To estimate the annual mortality risks from non-cancer
causes, we used similar parametric methods as above using
NHIS data linked to vital statistics. We estimated these risks
separately for non-cancer causes of death (cardiovascular
disease, trauma/accidents and other causes), and for each
sex and race strata, and weighted to account for the complex
sampling methods.23
Simulation Model and Estimation of Years of Life
Expectancy
We used a state-transition Markov model to simulate cancer
incidence and death for a cohort of 500,000 persons in each of
the four race/sex strata. This cohort size was based on the
minimum necessary to reduce the error of the main outcome
measure (racial difference in life expectancy) due to random-
ness in the stochastic model to less than 1%. Each person
entered the simulation at age 18. In each 1-year cycle, persons
could either be diagnosed with one or more specific cancers at
a particular stage at diagnosis, die from a non-cancer cause,
die from a specific cancer (assuming they had already been
diagnosed with the specific cancer) or live until the next year.
Persons were eligible to die from a specific cancer starting with
the same year of diagnosis. The process was repeated until the
person died.
From the simulated cohort, we then estimated the average
life expectancy for each race/sex stratum. The base case
estimates used the original risk estimates of cancer incidence,
stage and survival after cancer diagnosis for African Americans
and whites. We then conducted the simulation under three
alternative scenarios to estimate the contribution of racial
differences in cancer incidence, stage at diagnosis and survival
after diagnosis to racial differences in life expectancy. In
scenario 1, to estimate the impact of incidence, we multiplied








where IWjks and IBjks are the incidence risks for cancer j, at age
k, and stage s (note: s includes stages 1–4 and unknown stage
at diagnosis) among whites and African Americans, respec-
tively. This adjustment ensures that, for a given cancer and
age, equal numbers of African Americans and whites get
cancer, but allows African Americans and whites to have
different proportions diagnosed at each stage. In scenario 2,
to estimate the impact of stage at diagnosis, the numbers of
African Americans and whites diagnosed with cancer j at age k
remain the same as the base case, but instead we set the
proportion of persons diagnosed at each stage for African








In scenario 3, to estimate the impact of cancer survival
following diagnosis, the fatality risks (F) for persons with a
particular cancer j at age k and stage at diagnosis s were set to
be the same for African Americans and whites.
FBjks ¼ FWjks
We conducted an additional scenario in which we set the site-
specific cancer mortality risks for African Americans to be the
same as that among whites in order to examine the total
impact of a particular cancer on racial differences in life
expectancy. By comparing scenarios 1, 2 and 3 to the base
case simulation, we estimated the respective impact of disease
incidence, stage and survival after diagnosis on the racial
difference in life expectancy.
To estimate standard errors, we used a simulation method
approach in which we randomly drew 1,000 sets of parameter
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estimates, β, from each of the survival analyses.24 Each set of
parameters was drawn using the variance-covariance matrix of
the survival models under the assumption that the estimated
β’s have amultivariate normal sampling distribution. Thus, each
draw captures the uncertainty around β. For each set of
parameters, we ran the simulation and estimated life expectancy,
yielding 1,000 life expectancy estimates. We then calculated
confidence intervals and p-values using the percentile method.
WeusedC++ to create the simulationmodel andSAS version9.13
(Cary, NC) and STATA 8.0 (College Station, TX) to calculate all risk
estimates and 95% confidence intervals.
Simulation Model Validation
We checked the face and external validity of our results. To
validate our model, we compared mortality rate estimates, age-
standardized to the U.S. population in 2000,25 derived from
our simulation cohort and from National Vital Statistics
Reports.26–28 We also compared estimates from our simulation
model with previously reported estimates of years of potential
life lost due to cancer derived from NHIS data.14,29 For this
comparison, we analyzed our simulated cohort data to calculate
years of potential life lost before age 75 per 1,000 persons using
the same formula:
P
75age at death for those dying before 75 yearsð
of ageÞ  1000 n, where n is the number of persons at risk for
death.
RESULTS
Impact of Cancer Mortality on Racial Differences
in Years of Life Expectancy
Based on the simulation model, the average life expectancy at
birth is 76.61 years for white men and 71.90 years for black
men—a difference of 4.71 (95% CI: 4.59 to 4.76) years per
person. When mortality risk for all cancers combined is the
same for African Americans and whites, the racial difference in
average life expectancy decreases by 1.47 years (95% CI: 0.83
to 1.74) from 4.71 to 3.24 years (Table 1). (Note: the remaining
3.24 years difference in life expectancy between African
Americans and whites is due to racial differences in non-
cancer deaths.) If African-American men had the same lung
cancer mortality risk as white men, the racial difference in life
expectancy would drop 0.48 (95% CI: 0.42 to 0.55) years. This
impact is the largest among the specific types of cancer,
followed by prostate (0.28 years, 95% CI: 0.19 to 0.32),
esophageal (0.14 years, 95% CI: 0.08 to 0.18), head and neck
(0.14 years, 95% CI: 0.08 to 0.19) and colorectal cancer
(0.11 years, 95% CI: 0.01 to 0.14) (Table 1).
Among women, the estimated average life expectancy is
81.74 years for whites and 73.55 years for African Amer-
icans, a difference of 8.18 (95% CI: 8.10 to 8.26) years per
person. All cancers combined account for 0.91 (95% CI:
0.10 to 1.13) years of the life expectancy gap between
African American and white women. Among the specific
types of cancer, breast cancer has the biggest impact on the
racial difference in life expectancy, accounting for 0.15 years
(95% CI: 0.06 to 0.17). Colon cancer accounts for 0.12 years,
while cervical, pancreas and stomach cancer each account
for 0.09 years.
Contribution of Cancer Incidence, Stage
and Survival After Diagnosis on Racial Difference
in Years of Life Expectancy
For all cancers combined, we estimated that, among men,
racial differences in cancer incidence account for 1.12 (95% CI:
0.52 to 1.36) years of the total 1.47 years racial difference in
average life expectancy due to cancer. In contrast, stage
accounts for 0.17 (95% CI: −0.03 to 0.33) years, and survival
after diagnosis accounts for 0.21 (95% CI: 0.05 to 0.34) years.
Thus, among men, the racial difference in life expectancy due
to all cancers combined is mainly due to higher incidence risk
among African Americans than whites as opposed to later
stage of presentation or worse survival after diagnosis.
A similar pattern was found among men for specific types of
cancer (Fig. 1). The racial difference in lung cancer incidence
accounts for 0.47 (95% CI: 0.39 to 0.53) years of the racial
difference in average life expectancy compared with 0.004
(95% CI: −0.03 to 0.03) years due to stage at diagnosis and
0.03 (95% CI: −0.02 to 0.05) years due to survival after
diagnosis. For prostate cancer, incidence, stage and survival
after diagnosis accounts for 0.21 (95% CI: 0.13 to 0.26), 0.04
(95% CI: −0.001 to 0.09), and 0.05 (95% CI: 0.01 to 0.09)
years, respectively. Melanoma incidence accounts for −0.12
(95% CI: −0.07 to −0.18) years of the white-African American
difference in life expectancy, reflecting the fact that incidence of
melanoma is higher among whites than African Americans.
Table 1. White-African-American Difference in Years of Life
Expectancy at Birth, Stratified by Sex
Men Women
All causes of death 4.71 (4.59 to 4.76) 8.18 (8.10 to 8.26)
Attributable* to cancer of the:
Lung 0.48 (0.42 to 0.55) 0.08 (0.01 to 0.12)
Breast – 0.15 (0.06 to 0.17)
Colon/rectum 0.11 (0.01 to 0.14) 0.12 (0.04 to 0.16)
Liver 0.07 (0.03 to 0.11) 0.04 (−0.01 to 0.07)
Pancreas 0.06 (0.02 to 0.12) 0.09 (0.04 to 0.15)
Esophagus 0.14 (0.08 to 0.18) 0.05 (0.01 to 0.09)
Stomach 0.10 (0.03 to 0.14) 0.09 (0.01 to 0.13)
Uterine/ovary – 0.01 (−0.09 to 0.04)
Cervix – 0.09 (0.01 to 0.13)
Prostate 0.28 (0.19 to 0.32) –
Bladder or kidney 0.02 (−0.05 to 0.06) 0.06 (−0.03 to 0.08)
Leukemia or lymphoma 0.03 (−0.04 to 0.07) 0.02 (−0.03 to 0.06)
Head and neck 0.14 (0.08 to 0.19) 0.06 (−0.01 to 0.08)
Brain −0.03 (−0.06 to 0.005) −0.02 (−0.05 to 0.01)
Thyroid 0.06 (−0.02 to 0.07) 0.01 (−0.04 to 0.05)
Melanoma of the skin −0.04 (−0.10 to 0.005) −0.01 (−0.08 to 0.04)
Other non-epithelial
skin
0.01 (−0.03 to 0.03) 0.01 (−0.03 to 0.03)
Other cancers 0.03 (−0.03 to 0.07) 0.07 (0.002 to 0.10)
All cancers combined 1.47 (0.83 to 1.74) 0.91 (0.10 to 1.13)
*White-African American difference in life expectancy attributable to
specific cancers is estimated by setting the cancer-specific mortality rate
for African Americans to be the same as that among whites. Negative
numbers indicate that higher mortality rates exist among whites
compared to African Americans and that specific cancer accounts for a
decrease in the white-African American difference in life expectancy.
Positive numbers indicate lower mortality rates among African Americans
compared to whites and that specific cancer accounts for an increase in the
white-African American difference in life expectancy.
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The contribution of incidence relative to the contribution of
stage and survival after diagnosis is smaller among women
than among men. Among women, the racial difference in
incidence for all cancers combined accounts for 0.41 (95%
CI: −0.29 to 0.60) years of the racial difference in life
expectancy compared to 0.26 (95% CI: −0.06 to 0.40) years
due to stage and 0.31 (95% CI: 0.05 to 0.40) years due to
survival after diagnosis.
For women, incidence primarily accounts for the racial
differences in life expectancy due to cancer for most of the
specific types of cancer. (Fig. 2) However, breast cancer is one
exception to this pattern, for which survival accounts for more
of the racial gap in life expectancy (0.14 years) compared to
incidence (−0.063 years) or stage at diagnosis (0.085 years).
For cervical and colorectal cancer among women, incidence
still accounts for most of the racial difference in life expectancy.
However, stage at diagnosis has a larger relative impact as
compared to the pattern seen with other cancers. Uterine/
ovarian cancer incidence is higher among white women than
African American women and thus contributes −0.05 (95%
CI: −0.16 to −0.04) years.
Validation of Simulation Model
As expected, the impact of stage had a larger impact among
cancers with effective screening tests, such as breast, cervical
and colorectal cancer, than among other cancers. Consistent
with other studies,19 mortality rates were higher among
African Americans than whites for almost all cancers except
for melanoma. Also, the age-standardized mortality rate for
persons 25–74 years old was 745 deaths per 100,000 persons
from our simulation, compared with 773, 778 and 797 from
vital statistics data in 1999, 1998 and 1997, respectively. We
also estimated years of potential life lost from cancer, which
were similar to the results of a previous study14 (Fig. 3).
DISCUSSION
Previous studies suggest a variety of explanations for racial
disparities in cancer mortality. For example, African Amer-
icans may have greater exposure to carcinogens, such as
tobacco,30,31 and a greater genetic predisposition to getting
cancers.32 African Americans also tend to present at a later
and less curable stage,33,34 perhaps due to lower screening
rates and delays in seeking care for symptoms.34,35 They are
also less likely to receive appropriate cancer treatment5,36–42
and have more comorbid conditions.43 Each of these explana-
tions suggests a different target for intervention to eliminate
cancer disparities. As researchers, public health officials and
policymakers decide which potential interventions to pursue, it
would be particularly helpful to understand where along the
course of cancer that disparities develop and the contribution
of racial differences in cancer incidence, stage at diagnosis and
survival after diagnosis to the racial gap in life expectancy.
In the present study, we used simulation modeling to
estimate how much of the racial gap in life expectancy would
decline if African Americans, compared to whites, had the
Figure 1. Racial difference (white-African American) in years of life
expectancy (LE) among men attributable to racial differences in
cancer incidence, stage at presentation and survival after cancer
diagnosis. *p<0.05, testing the null hypothesis that the change of life
expectancy difference is zero. Negative numbers indicate that
higher incidence rates, fatality rates or later stage at diagnosis
occurs among whites compared to African Americans and thus
accounts for a decrease in the white-African American difference in
life expectancy. Positive numbers indicate that higher incidence
rates, fatality rates or later stage at diagnosis occurs among African
Americans compared to whites and thus accounts for an increase in
the white-African American difference in life expectancy.
Figure 2. Racial difference (white-African American) in years of life
expectancy (LE) among women attributable to racial differences in
cancer incidence, stage at presentation and survival after cancer
diagnosis. *p<0.05, testing the null hypothesis that the change of life
expectancydifference is zero. Negative numbers indicate that higher
incidence rates, fatality rates or later stage at diagnosis occurs
among whites compared to African Americans and thus accounts for
a decrease in the white-African American difference in life expec-
tancy. Positive numbers indicate that higher incidence rates, fatality
rates or later stage at diagnosis occurs among African Americans
compared to whites and thus accounts for an increase in the white-
African American difference in life expectancy.
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same incidence rates, stage at presentation and survival after
cancer as whites. We found for all cancers combined, and for
most specific cancers, that differences in cancer incidence
contributed substantially more to the racial difference in
cancer mortality than cancer stage or survival after diagnosis,
particularly among men. Lung cancer incidence had a partic-
ularly large impact among men contributing almost half of a
year difference in life expectancy. This is more than the impact
of stage and survival after diagnosis for all cancers combined
and suggests that smoking cessation might be a particularly
effective way to reduce racial disparities in cancer mortality
among men. Racial differences in the incidence of other
cancers, such as prostate, gastrointestinal and head and neck,
also account for a substantial amount of the life expectancy
disparity. Although we do not have proven preventive strategies
specific for these cancers, smoking cessation is likely to have a
significant impact. Furthermore, 5-alpha-reductase inhibitors
may reduce prostate cancer risk,44 and thus may be a potential
intervention to reduce cancer disparities if future studies confirm
that a mortality benefit exists.
The contribution of stage at diagnosis to the racial gap in life
expectancy was not statistically significant for any cancer type.
Despite this, it is worth noting that the impact of stage was
larger for cancers of the breast, colon/rectum and cervix than
for other cancers, consistent with what we expected given that
effective screening tests exist for these cancers. These results
suggest that focusing on better screening for these cancers
among African Americans may also be potentially important
targets for reducing cancer mortality disparities.
Differences in survival after diagnosis had a statistically
significant impact on only two cancers—breast and prostate,
accounting for 0.15 and 0.05 years difference in life expectancy,
respectively. This may be due to the fact that African Americans
are less likely to receive appropriate breast and prostate cancer
treatment,33,36,45,46 and may also be due to a greater burden of
comorbid illnesses among African Americans, which also worsens
survival from cancer.43
Of note, the results of our simulation model have strong face
and external validity. Years of potential life lost from specific
cancers were remarkably similar between this study and a
previously published comparison study, even though themodels
and the source data were substantially different between these
studies.14 The comparison study used cancer-specific mortality
rates from NHIS data and simulated persons as they transi-
tioned from being alive directly to death from cancer.14 The
current study used cancer-specific incidence and fatality rates
based on SEER data and simulated persons as they transitioned
from being alive without cancer to having cancer and then to
death. Of note, the previous study results were validated using
life table methods.14 We found relatively small differences in
mortality rates estimated from our study compared to vital
statistics results. The small differencesmay be due to differences
in data samples. Specifically, we estimated mortality rates using
SEER data, which include only a subset of cancer deaths in the
US, and NHIS data, which exclude institutionalized and home-
less persons. Vital statistics data include all deaths in the US.
Although our study has implications for cancer prevention,
screening and treatment, we did not examine the impact of
specific interventions. It is possible, for example, that differences
in survival after diagnosis may be due to more aggressive tumors
among African Americans.47–50 Similarly, the contribution of
differences in lung cancer incidence suggests that the racial
difference in tobacco use is important, but tobaccomay also have
a more deleterious effect among African Americans because they
tend to metabolize cigarette carcinogens more slowly than
whites.31 The identification and removal of pre-malignant polyps
may lead to a lower incidence of colon cancer.51 Thus, racial
differences in colonoscopy may have a larger impact on racial
differences in colorectal mortality than the amount suggested by
the difference due to stage at presentation.
Although SEER is a population-based registry, the data are
collected from distinct geographic regions that may not
represent national patterns of cancer nor reflect racial differences
in cancer that occur in a particular region. Althoughwe separately
analyzed persons with unstaged cancer, African Americans may
be less likely to receive complete diagnostic evaluations for
staging,52 which could potentially bias our results. Mortality data
from SEER are also based on death certificate data, which may
contain inaccuracies about the underlying cause of death.
The National Healthcare Disparities Reports have primarily
focused on breast and colorectal cancer mortality and screen-
ing,12,13 and our study underscores the importance of these
targets. In addition, other key targets should include smoking
cessation, given the large impact of cancer incidence for most
types of cancer, especially for lung cancer, and also include
survival among those diagnosed with prostate cancer. Continu-
ing to improve cancer treatment and screening is undoubtedly
Figure 3. Comparison of SEER and NHIS data on years of potential
life lost (YPLL) due to specific cancers and all cancers combined.
YPLL = years of potential life lost before age 75 per 1,000 persons,
calculated as
P
75age at death for those dying beforeð
75 years of ageÞnÞ  1000, where n is the number of persons at
risk for death in the population. Other GI = other gastrointestinal
cancers, including esophageal, pancreatic and liver.
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important to improving life expectancy and quality of life for all
adults, yet substantial disparities in cancer mortality will persist
unless we can findways to address the enormous impact of racial
differences in cancer incidence.
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Table 2. White-African-American Difference Among Men in Years of Life Expectancy Attributable to Incidence, Stage at Diagnosis and
Survival After Cancer Diagnosis, by Cancer Type (95% CI)
Cancer type Incidence Stage Survival Total
Lung 0.47 (0.39 to 0.53) 0.004 (−0.03 to 0.03) 0.03 (−0.02 to 0.05) 0.48 (0.42 to 0.55)
Breast – – – –
Colorectal 0.07 (−0.03 to 0.08) 0.03 (−0.02 to 0.06) 0.01 (−0.01 to 0.06) 0.11 (0.01 to 0.14)
Liver 0.07 (0.03 to 0.11) −0.003 (−0.02 to 0.02) 0.002 (−0.01 to 0.02) 0.07 (0.03 to 0.11)
Pancreas 0.06 (0.02 to 0.12) −0.01 (−0.02 to 0.01) −0.001 (−0.01 to 0.01) 0.06 (0.02 to 0.12)
Esophagus 0.14 (0.08 to 0.18) −0.002 (−0.02 to 0.02) 0.01 (−0.01 to 0.04) 0.14 (0.08 to 0.18)
Stomach 0.11 (0.03 to 0.14) 0.01 (−0.03 to 0.03) 0.004 (−0.01 to 0.01) 0.10 (0.03 to 0.14)
Uterine/ovary – – – –
Cervix – – – –
Prostate 0.21 (0.13 to 0.26) 0.04 (−0.001 to 0.09) 0.05 (0.01 to 0.09) 0.28 (0.19 to 0.32)
Urologic −0.05 (−0.11 to 0.01) 0.05 (−0.01 to 0.07) 0.02 (−0.01 to 0.04) 0.02 (−0.05 to 0.06)
Hematologic 0.02 (−0.06 to 0.03) 0.01 (−0.02 to 0.03) 0.03 (−0.01 to 0.05) 0.03 (−0.04 to 0.07)
Head and neck 0.09 (0.03 to 0.13) 0.02 (−0.004 to 0.06) 0.04 (−0.001 to 0.08) 0.14 (0.08 to 0.19)
Brain −0.02 (−0.05 to 0.01) −0.005 (−0.02 to 0.01) 0.0002 (−0.002 to 0.002) −0.03 (−0.06 to 0.005)
Thyroid 0.05 (−0.02 to 0.07) 0.01 (−0.02 to 0.04) 0.002 (−0.01 to 0.01) 0.06 (−0.02 to 0.07)
Melanoma −0.12 (−0.18 to −0.07) 0.01 (−0.02 to 0.04) −0.001 (−0.01 to 0.02) −0.04 (−0.10 to 0.00)
Other skin 0.01 (−0.03 to 0.03) 0.002 (−0.01 to 0.01) 0.001 (−0.01 to 0.00) 0.01 (−0.03 to 0.03)
Other cancers 0.005 (−0.04 to 0.05) 0.02 (−0.03 to 0.04) 0.02 (−0.01 to 0.03) 0.03 (−0.03 to 0.07)
Total 1.12 (0.52 to 1.36) 0.17 (−0.03 to 0.33) 0.21 (0.05 to 0.34) 1.47 (0.83 to 1.74)
Numbers in bold indicate statistically significant differences at p<0.05
These numbers are represented in Figure 1
Table 3. White-African American Difference Among Women in Years of Life Expectancy Attributable to Incidence, Stage at Diagnosis and
Survival After Cancer Diagnosis, by Cancer Type (95% CI)
Cancer type Incidence Stage Survival Total
Lung 0.08 (0.003 to 0.11) 0.001 (−0.03 to 0.03) 0.03 (−0.02 to 0.03) 0.08 (0.01 to 0.12)
Breast −0.06 (−0.12 to −0.01) 0.08 (0.01 to 0.11) 0.14 (0.05 to 0.16) 0.15 (0.06 to 0.17)
Colorectal 0.06 (−0.01 to 0.11) 0.04 (−0.03 to 0.06) 0.02 (−0.02 to 0.07) 0.12 (0.04 to 0.16)
Liver 0.03 (−0.01 to 0.07) 0.01 (−0.02 to 0.02) 0.003 (−0.01 to 0.02) 0.04 (−0.01 to 0.07)
Pancreas 0.10 (0.04 to 0.15) 0.002 (−0.02 to 0.02) 0.001 (−0.01 to 0.01) 0.09 (0.04 to 0.15)
Esophagus 0.04 (0.01 to 0.08) 0.002 (−0.01 to 0.01) 0.01 (−0.01 to 0.02) 0.05 (0.01 to 0.09)
Stomach 0.09 (0.01 to 0.13) −0.003 (−0.04 to 0.02) −0.003 (−0.01 to 0.01) 0.09 (0.01 to 0.13)
Uterine/ovary −0.05 (−0.16 to −0.04) 0.03 (−0.01 to 0.07) 0.02 (−0.02 to 0.05) 0.01 (−0.09 to 0.04)
Cervix 0.06 (−0.02 to 0.10) 0.04 (−0.01 to 0.06) 0.02 (−0.01 to 0.03) 0.09 (0.01 to 0.13)
Prostate − – – –
Urologic 0.03 (−0.05 to 0.06) 0.01 (−0.02 to 0.05) 0.01 (−0.02 to 0.04) 0.06 (−0.03 to 0.08)
Hematologic 0.005 (−0.04 to 0.05) 0.01 (−0.02 to 0.03) 0.02 (−0.03 to 0.04) 0.02 (−0.03 to 0.06)
Head and neck 0.03 (−0.03 to 0.06) 0.01 (−0.01 to 0.03) 0.03 (−0.02 to 0.04) 0.06 (−0.01 to 0.08)
Brain −0.01 (−0.05 to 0.01) −0.01 (−0.02 to 0.01) 0.001 (−0.002 to 0.002) −0.02 (−0.05 to 0.01)
Thyroid 0.001 (−0.04 to 0.04) 0.001 (−0.01 to 0.02) 0.001 (−0.01 to 0.01) 0.01 (−0.04 to 0.05)
Melanoma −0.08 (−0.15 to −0.03) 0.01 (−0.02 to 0.05) 0.01 (−0.01 to 0.02) −0.01 (−0.08 to 0.04)
Other skin 0.02 (−0.03 to 0.03) −0.0004 (−0.005 to 0.01) 0.001 (−0.01 to 0.003) 0.01 (−0.03 to 0.03)
Other cancers 0.06 (0 to 0.09) 0.01 (−0.02 to 0.04) 0.02 (−0.02 to 0.03) 0.07 (0.002 to 0.10)
Total 0.41 (−0.29 to 0.60) 0.26 (−0.06 to 0.40) 0.31 (0.05 to 0.40) 0.91 (0.10 to 1.13)
Numbers in bold indicate statistically significant differences at p<0.05
These numbers are represented in Figure 2
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